Abstract 12836: Cardiovascular Disease Profile in Children With Hcm (aspire-hcm): A Canadian Cross-Sectional Study

Abstract

Introduction: Adults with hypertrophic cardiomyopathy (HCM) have been shown to have abnormal cardiovascular (CV) health, leading to long-term problems. However, little is known about the CV health of children with HCM. Given the emphasis placed on physical activity restrictions in patients with HCM, effective communication regarding the importance of a heart-healthy lifestyle may be lacking. Therefore, the aim of this study was to assess CV health in a cohort of children with HCM across Canada. Methods: Children with HCM, ages 10-18 years old, were recruited from 10 Canadian sites and underwent CV health screening including: body mass index (BMI), central adiposity assessment via the waist-to-height ratio (WHtR, ≥0.5 considered abnormal), non-fasting lipid profile, (abnormal cholesterol being >4.4 mmol/L); systolic blood pressure (≥95th percentile considered hypertensive;0 and a 2-week period of activity assessment using a wrist Fitbit. An average daily step count ≥12,500 was used as a surrogate for ≥60 minutes of moderate to vigorous physical activity. Results: Forty-six patients with HCM were included [76% male; median age 15.4 years (IQR 13.7, 16.7)]. The median BMI percentile was 85.0 (IQR 58.5, 97.0) with 56.6% being overweight or obese (BMI >85th percentile). The WHtR was a median of 0.51 (IQR 0.43-0.55), with 55.6% being ≥0.50. The median systolic blood pressure was 113.5 mmHg (IQR 101.8-123.0), with 10.8% having measurements in the hypertensive range. The median cholesterol was 3.7 mmol/L (IQR 3.4-4.4), with 29% of patients having an elevated cholesterol. Average daily step count ≥12,500 occurred in 14% of the cohort with the median average steps per day being 7,590 (IQR 5,205-10,894). Conclusions: The majority of Canadian children with HCM have evidence of physical inactivity and an adverse CV risk profile. In order to prevent poor CV health outcomes in adulthood, interventions are required to target these risk factors in children with HCM.